How Alzheimer’s Disease Is Diagnosed Today

See which clinic exams, brain scans, spinal-fluid tests and the new blood test confirm Alzheimer's and guide next steps.

Alzheimer's disease, a brain disorder that harms memory and thinking, is diagnosed today with exams plus amyloid and tau testing. Doctors combine history, cognitive testing, lab work, brain imaging, spinal-fluid analysis and a cleared blood test in suitable cases. A clinician must interpret every result alongside symptoms and health history. No single score decides the diagnosis, and follow-up testing often clarifies borderline findings.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

What happens at the first visit?

Doctors start with medical history and a neurologic exam. They ask a family member about daily changes, safety and function.

They test memory, problem-solving, attention and language with brief tasks. The National Institute on Aging describes in its diagnostic guidance a core workup with three parts: Abnormal cognitive scores do not prove Alzheimer's by themselves. They show the pattern and severity doctors must explain.

  • history, neurologic exam and cognitive tests of memory, problem-solving, attention and language
  • standard lab tests to rule out other medical causes of confusion
  • careful review of medicines, mood, sleep and daily function

What do scans and spinal fluid add?

Brain imaging supports the clinical picture. CT or MRI checks for shrinkage, vessel injury or another cause of symptoms. Amyloid and tau PET scans can reveal plaques and tangles, the hallmark brain changes.

Spinal fluid collected by lumbar puncture adds chemical proof. The lab measures amyloid-beta and phosphorylated and total tau. Results support Alzheimer's or point toward a related dementia.

Why can one biomarker confirm Alzheimer's now?

In 2024 the Alzheimer's Association Workgroup defined Alzheimer's as a biological process, not only a symptom stage. Under that framework one abnormal Core 1 biomarker suffices for diagnosis. Qualifying markers include amyloid PET, qualifying spinal-fluid amyloid and tau ratios, and highly accurate plasma p-tau such as p-tau217.

Jack et al. in Alzheimer's and Dementia describe this shift in the revised 2024 criteria. This means biology can establish Alzheimer's even when care planning focuses on symptoms. Staging and treatment choices still depend on the person's exam, function and other test results.

What does the cleared blood test change?

The Food and Drug Administration states in its clearance notice that on May 16, 2025 it cleared Fujirebio's Lumipulse G pTau217/beta-Amyloid 1-42 plasma-ratio test. It is the first blood-based aid for detecting amyloid pathology in adults 55 and older with cognitive signs seen in specialty care. Validation studied 499 adults with cognitive impairment against PET or spinal fluid. In its test summary, the American Academy of Family Physicians reports 91.7 percent agreement for positives and 97.3 percent for negatives.

The Alzheimer's Association blood-biomarker guideline says tests with at least 90 percent sensitivity and 75 percent specificity can triage cases. Negatives largely rule out pathology, while positives need PET or spinal-fluid confirmation. Blood tests are not standalone screening tools and need clinical interpretation. Borderline results or other illnesses trigger repeat blood testing or PET or spinal-fluid follow-up.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.